US scientists are undertaking a clinical trial to decode the efficacy of a long-acting antibody against Long Covid -- a condition that affects at least 65 million people worldwide. 

Long Covid affects people after an infection caused by the SARS-CoV-2 virus. The condition not properly defined yet presents with more than 200 symptoms.